enGene Therapeutics (ENGN) Q3 2026 earnings summary

Executive summary

• The company is focused on advancing detalimogene for high-risk, BCG-unresponsive NMIBC and bladder cancer, with pivotal Phase 2 trials and regulatory milestones targeted for Q4 2026.

• Interim results from the LEGEND trial showed a 54% any-time complete response rate, with ongoing data collection and a new cohort using a surfactant bladder rinse.

• In June 2026, a strategic restructuring reduced workforce by ~50% to preserve cash and focus on key milestones, including BLA submission planning for detalimogene.

• Board leadership transitioned in July 2026 to support regulatory and commercial readiness.

Financial highlights

• Net loss was $32.5 million for the quarter and $92.5 million for the nine months ended July 31, 2026, with net loss per share at $0.47 for the quarter.

• Operating expenses for the quarter were $34.0 million, up from $29.9 million year-over-year, mainly due to increased general and administrative costs and restructuring.

• Cash, cash equivalents, and marketable securities totaled $266.3 million as of July 31, 2026, up from $202.3 million as of October 31, 2025.

• No revenue was generated; the company remains pre-commercial.

Outlook and guidance

• Existing cash and equivalents are expected to fund operations and debt obligations for at least the next 12 months from the report date.

• Additional funding will be needed to support ongoing operations and commercialization efforts beyond the current cash runway.

• Key upcoming milestones include updated pivotal cohort data, FDA engagement, and planned BLA submission for detalimogene in Q4 2026, with potential FDA approval decision in 2027.